A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol

Phase 3 Terminated 366 enrolled Eli Lilly and Company

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the ACCENTUATE study is to evaluate whether the study drug known as evacetrapib is effective in treating participants with high cholesterol and atherosclerotic cardiovascular disease (ASCVD) and/or diabetes.

Timeline

Start: 2014-10
Primary completion: 2015-12
Completion: 2015-12

Publications

Nicholls SJ, Ray KK, Ballantyne CM, Beacham LA, Miller DL, Ruotolo G, Nissen SE, Riesmeyer JS; ACCENTUATE Investigators. Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial. Atherosclerosis. 2017 Jun;261:12-18. doi: 10.1016/j.atherosclerosis.2017.04.008. Epub 2017 Apr 8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Atorvastatin	Small molecule	40 mg	Oral
Subject	Atorvastatin	Small molecule	80 mg	Oral
Subject	Evacetrapib	Small molecule	130 mg	Oral
Comparator	Ezetimibe	Unknown	10 mg	Oral

A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol

Summary

Timeline

Publications

Drugs

Indications